CAR-T & Cellular Therapy
Novel immune therapies in MDS and challenges in this space
Myelodysplastic syndromes (MDS) represent a group of heterogeneous diseases which remain a challenge to treat, and several novel therapies are…
Date: 7th February 2023
NHL highlights at ASH 2022: updates in MCL, the role of transplantation, and novel bispecific antibodies
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 2nd February 2023
T-cell lymphoma highlights at ASH 2022: unmet needs, clinical trial updates & future outlooks
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans, LA,…
Date: 20th January 2023
Myeloma highlights at ASH 2022: improving access to CAR-T therapy & future outlooks
The 64th American Society of Hematology (ASH) Annual Meeting and Exposition took place on December 10-13, 2022, in New Orleans,…
Date: 3rd January 2023
iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 30th November 2022
iwAL 2022 Session IV: the evolving treatment landscape in ALL and the growing role of immunotherapies
The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the…
Date: 22nd November 2022
iwNHL Session III: exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 18th November 2022
iwNHL Session II: understanding and harnessing the immune microenvironment against lymphoma
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 9th November 2022
iwNHL 2022 Session I: advances in the treatment of T-cell lymphoma
The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in…
Date: 26th October 2022
The need for more effective first-line therapies in MDS
The treatment and management of myelodysplastic syndromes (MDS) remains a challenge due to the heterogeneity of the disease, and early…
Date: 7th September 2022
Myeloma 2022: day two highlights
There were several fascinating sessions and discussions at the Myeloma 2022 meeting that took place in Scottsdale, AZ. Topics that…
Date: 2nd September 2022
The promise of CAR-T therapy in CLL and challenges in the field
The treatment landscape of chronic lymphocytic leukemia (CLL) has greatly transformed over the years with the introduction of several agents,…
Date: 31st August 2022
